Payment overview · 2025
General Payments
$92.66
4 reported records · 4 companies
Healthcare provider profile · identity verified
Oricel Aguiar, MD
Allopathic & Osteopathic Physicians|General Practice · MIAMI, FL · NPI 1942624036
Verified facts
What the public records show
CMS Open Payments records show Oricel Aguiar, MD received $92.66 in general payments during 2025 across 4 reported records.
Exact Sciences Corporation accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.96 | 36.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.25 | 30.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.00 | 17.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.45 | 15.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $92.66 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 452 | 151 |
| Losartan Potassium | Losartan Potassium | 352 | 113 |
| Diclofenac Sodium | Diclofenac Sodium | 336 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 326 | 110 |
| Gabapentin | Gabapentin | 304 | 101 |
| Famotidine | Famotidine | 261 | 94 |
| Omeprazole | Omeprazole | 256 | 84 |
| Montelukast Sodium | Montelukast Sodium | 246 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 233 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 60 |
| Azithromycin | Azithromycin | 181 | 123 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 57 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 169 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 57 |
| Prednisone | Prednisone | 157 | 88 |
| Lisinopril | Lisinopril | 152 | 49 |
| Metformin Hcl | Metformin Hcl | 145 | 53 |
| Furosemide | Furosemide | 142 | 50 |
| Meloxicam | Meloxicam | 141 | 59 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 140 | 55 |
| Memantine Hcl | Memantine Hcl | 122 | 46 |
| Ibuprofen | Ibuprofen | 119 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 46 |
| Baclofen | Baclofen | 106 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 44 |
| Mirtazapine | Mirtazapine | 101 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 31 |
| Ozempic | Semaglutide | 91 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 83 | 49 |
| Glipizide | Glipizide | 79 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 78 | 61 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 77 | 37 |
| Ketoconazole | Ketoconazole | 74 | 33 |
| Synjardy | Empagliflozin/Metformin Hcl | 69 | 19 |
| Levofloxacin | Levofloxacin | 68 | 52 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 67 | 12 |
| Celecoxib | Celecoxib | 64 | 30 |
| Latanoprost | Latanoprost | 64 | 11 |
| Jardiance | Empagliflozin | 61 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 12 |
| Sertraline Hcl | Sertraline Hcl | 59 | 25 |
| Donepezil Hcl | Donepezil Hcl | 56 | 21 |
| Eliquis | Apixaban | 56 | 13 |
| Fenofibrate | Fenofibrate | 56 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 18 |
| Linzess | Linaclotide | 52 | 26 |
| Ciclopirox | Ciclopirox | 50 | 18 |
| Hydrocortisone | Hydrocortisone | 50 | 22 |
| Allopurinol | Allopurinol | 49 | 17 |
| Farxiga | Dapagliflozin Propanediol | 47 | 15 |
| Methocarbamol | Methocarbamol | 47 | 20 |
| Enalapril Maleate | Enalapril Maleate | 46 | 18 |
| Nifedipine Er | Nifedipine | 45 | 16 |
| Naproxen | Naproxen | 44 | 17 |
| Alendronate Sodium | Alendronate Sodium | 43 | 14 |
| Pentoxifylline | Pentoxifylline | 43 | 15 |
| Atenolol | Atenolol | 41 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 36 |
| Trazodone Hcl | Trazodone Hcl | 40 | 20 |
| Ciclopirox | Ciclopirox Olamine | 38 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 24 |
| Azelastine Hcl | Azelastine Hcl | 37 | 19 |
| Meclizine Hcl | Meclizine Hcl | 37 | 33 |
| Mupirocin | Mupirocin | 37 | 28 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 36 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 35 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 34 | 18 |
| Carvedilol | Carvedilol | 34 | 11 |
| Ezetimibe | Ezetimibe | 34 | 14 |
| Finasteride | Finasteride | 33 | 12 |
| Repaglinide | Repaglinide | 33 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | 14 |
| Lactulose | Lactulose | 29 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Folic Acid | Folic Acid | 28 | 14 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 17 |
| Buspirone Hcl | Buspirone Hcl | 25 | 12 |
| Repatha Syringe | Evolocumab | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 23 | 20 |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | 11 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Alprazolam | Alprazolam | 20 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Terconazole | Terconazole | 19 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 17 | 11 |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Valsartan | Valsartan | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Alphagan P | Brimonidine Tartrate | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $92.66 · 4 records | Exact Sciences Corporation | AIRSUPRA, Cologuard Collection Kit, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error